Zealand Pharma A/S (OTCMKTS:ZLDPF) Rating Increased to Strong-Buy at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) to a strong-buy rating in a report released on Tuesday morning,Zacks.com reports.

Separately, JPMorgan Chase & Co. started coverage on shares of Zealand Pharma A/S in a report on Friday, November 8th. They issued an “overweight” rating on the stock.

Zealand Pharma A/S Stock Up 2.1 %

Shares of ZLDPF opened at $102.98 on Tuesday. The company’s fifty day moving average is $102.26 and its two-hundred day moving average is $117.80. The firm has a market cap of $7.31 billion, a PE ratio of -42.38 and a beta of 0.89. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03. Zealand Pharma A/S has a fifty-two week low of $65.26 and a fifty-two week high of $141.74.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.